112 results about "Mometasone furoate" patented technology

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.

Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate and processes for preparing the same.

Disclosed are methods of introducing a suspension or solution of a medicament, preferably mometasone furoate anhydrous, into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of introducing mometasone furoate anhydrous, a surfactant and a chlorofluorocarbon free propellant into a vessel that is held under pressure to form a suspension or solution, circulating said suspension or solution from the vessel through a line which includes a filling head, bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container, introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container, withdrawing said filling head from said metered dose inhaler container, and sealing said metered dose inhaler container, as well as the products produced thereby having an improved particle size distribution of the active ingredients in metered dose inhalers.

The invention relates to treating chronic obstructive pulmonary disease, involving the administration by inhalation of mometasone furoate particles in daily doses where at least about 250 μg of the inhaled particles have sizes equal to or less than 6.5 μm.

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

The invention belongs to synthetic methods of medicines, and in particular relates to a method for synthesizing mometasone furoate. According to the method, chlorination is carried out to obtain a compound 2 while an esterification reaction is carried out between a compound 1 and furoyl chloride, and ring opening operation is carried out on the compound 2 in the presence of hydrochloric acid to generate mometasone furoate. According to the method, the defects of long process route, complex reaction system, long consumed time and the like of the original process are effectively overcome. The method provided by the invention is simple in process, mild in reaction condition, high in yield, low in cost, high in quality, and low-price and easily-available in raw and auxiliary materials, and is suitable for industrial production.

The invention relates to a topically applied composition containing povidone iodine and mometasone furoate, in particular to a topically applied pharmaceutical composition which contains the micronized mometasone furoate, the povidone iodine and one or more physiologically acceptable excipients applicable to topical application; and in the pharmaceutical composition, the content of the povidone iodine is 1%-10%, and the content of the mometasone furoate is 0.01%-0.1%.

The invention relates to the technical field of an external preparation medicament, in particular to an external preparation medicament containing momestasone furoate. The external preparation medicament is prepared from the following raw materials in part by weight: 15 parts of the momestasone furoate, 45 parts of hexadecyl-octadecyl alcohol, 7.5 parts of glyceryl monostearate, 5 parts of beeswax, 8 parts of triethanolamine, 35 parts of light liquid paraffin, 2 parts of sodium lauryl sulfate, 8 parts of sodium lauryl sulfate, 25 parts of propylene glycol, 1 part of Hydroxy acetate, 2 parts of tween-80, and the balance of purified water which is added to ensure that the total weight is 500 parts. The cream has better moisture retention and stability because the humectant combination of the triethanolamine and the propylene glycol is adopted.

The invention provides a functional preparation for adjuvant therapy of atopic dermatitis AD and a preparation method thereof. The functional preparation comprising raw material components in parts by weight: 0.2-1 part of sodium hyaluronate, 5-10 parts of emulsifying thickening agent, 5-10 parts of grease and the balance of de-ionized water which enables the total weight to be 100 parts. The functional preparation provided by the invention is the functional preparation containing sodium hyaluronate and is combined with mometasone furoate emulsifiable paste to obviously improve a xerotic eczema symptom, effectively recover a skin barrier function, and reduce the recurrence; the curative effect of the functional preparation combined with mometasone furoate emulsifiable paste is better than that of the single use of the mometasone furoate emulsifiable paste; and the functional preparation can be used for the adjuvant therapy of eczematous dermatitis diseases, has the good curative effect and safety, and reduces the reoccurrence.

The invention relates to an external medicinal preparation, and particularly relates to an external medicine containing mometasone furoate and a preparation method thereof. In order to achieve the purpose, the invention provides mometasone furoate cream. The mometasone furoate cream is prepared from the following raw materials in parts by weight: 0.5 to 2 parts of mometasone furoate, 75 to 150 parts of an oil phase regulator, 30 to 50 parts of a consistency regulator, 60 to 100 parts of a humectant, 80 to 120 parts of a co-emulsifier, 60 to 90 parts of a co-solvent, 1 to 3 parts of a brightening agent, 30 to 50 parts of an emulsifier, 0.3 to 1 part of a preservative and 500 to 600 parts of water. The mometasone furoate cream prepared by the preparation method disclosed by the invention hasthe advantages of reduced impurity content, increased yield, advanced process, simple method and high yield.

The invention discloses nasal in-situ gel containing mometasone furoate and an H1 receptor antagonist. The nasal in-situ gel is prepared from mometasone furoate serving as an active ingredient and/or a hydrate of mometasone furoate, one or more H1 receptor antagonists, an environmentally-sensitive hydrophilic gel material, other pharmaceutically acceptable auxiliary materials and the balance of water.

The invention provides an intranasal medicinal composition. The intranasal medicinal composition contains bilastine, mometasone furoate, and thaumatin serving as a bitterness and irritation alleviator.

The invention provides a preparation method of mometasone furoate gelatin. The mometasone furoate gelatin is prepared from the following raw materials and auxiliary materials in proportion by weight of 1.0g of mometasone furoate, 8.0-10.0g of carbomer, 4.0-6.0g of triethanolamine, 50.0g of medical ethanol, 150.0g of glycerine, and 0-1.5g of ethylparaben, and purified water is added until the totalweight is 1000g, wherein the pH value of the mometasone furoate gelatin is 5.5-6.5, and the mass ratio of the triethanolamine to the carbomer is 0.40-0.55; single unknown impurities of the mometasonefuroate gelatin do not exceed 0.2%; the total impurities are not greater than 1.0%, and the mometasone furoate gelatin is stable under the high-temperature illumination condition. Besides, radix angelicae pubescentis, herba selaginellae, Chinese arborvitae twigs and leaves, hedyotis diffusa, a pharmaceutic adjuvant, azone and rice milk, which are added, have favorable treatment effect on treatment of foot fracture.

The invention discloses a nasal nano-preparation mometasone furoate liquid crystal gel nanoparticle and a preparation method thereof. The nanoparticle consists of 0.06-0.09wt% of mometasone furoate, 30-50wt% of a liquid crystal material, 20-30wt% of phosphatidylcholine, 5-15wt% of a surfactant, 5-15wt% of a solvent and 0-40wt% of de-ionized water. The preparation method of the liquid crystal gel nanoparticle comprises the following steps: firstly, uniformly mixing all raw materials except for the solvent and the de-ionized water, and adding the solvent and promoting dispersion; and then, adding the water, and implementing further dispersion via a high shear homogenizer or ultrasonic wave, so that a finished product (the liquid crystal gel nanoparticle) is obtained. The prepared mometasonefuroate liquid crystal gel nanoparticle is small in particle size, high in encapsulation efficiency, good in medicine absorption rate, good in sustained release effect and good in therapeutic effect;and the liquid crystal gel nanoparticle is obvious curative effect on allergic rhinitis and bacterial rhinitis.

Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and processes for preparing the same.

The invention relates to a 8DM derivative, and a method for synthesizing mometasone furoate from the 8DM derivative. The method comprises the following steps: carrying out an esterification reaction on a compound 1 and furoyl chloride to generate a compound 2 which is the 8DM derivative, and simultaneously carrying out a ring opening reaction and a 21th position chlorination reaction on the compound 2 in the presence of concentrated hydrochloric acid to generate a compound 3 which is mometasone furoate. The disadvantages of long route, complex reaction system and long time of original technologies are effectively solved in the invention. The method has the advantages of simple process, mild reaction conditions, high yield, low cost, high quality, cheap and easily available raw and auxiliary materials, and suitableness for industrial production.

The invention relates to a pharmaceutical composition which is prepared from an active component and drug auxiliary materials and is directly acted on skin. The pharmaceutical composition is characterized in that the active component contains one of mometasone furoate and azulene sulfonic acid or salt thereof.

Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.

The invention discloses mometasone furoate cream and a preparation method thereof. The mometasone furoate cream is prepared through the technology method comprising the steps that mometasone furoate is mixed with a mixture of Tween-80 and anhydrous citric acid, and then the obtained mixture is added into an aqueous propylene glycol solution. The mometasone furoate cream has the better stability, the appropriate retention amount in the skin and the lower skin penetration amount.

The invention provides a content determination method of mometasone furoate cream, and relates to the technical field of chemical detection. The content determination method comprises the following steps: preparing a beclomethasone propionate internal standard solution; preparing a mometasone furoate reference substance solution; preparing a mometasone furoate cream test solution; and measuring the content by an internal standard method. By improving the previous detection standard and resetting the detection conditions, the problems of leading peak pattern and poor symmetry of the main peak in the existing standard content determination method are effectively solved, so that the content detection of the mometasone furoate cream is more accurate and reliable.